1 Min Read
Sept 29 (Reuters) - Galena Biopharma Inc :
* Currently enrolling HER2 1+ and 2+ node positive, high-risk node negative patients to study NeuVax in combination with trastuzumab Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.